Gilles Schang

Specializes in preclinical and clinical development of drugs

Manufactures medical prostheses for vertebral implants

BPIfrance Investissement is an active manager focused on small, medium and intermdiate-sized businesses with high-growth potential. They favor sectors related to industry and technology and focus on investments in France. The firm invests either directly through dedicated investment funds or indirectly through private equity funds, partnerships and fund of funds managed by third parties. They invest across development stages, from start-ups to small LBO operations resulting from corporate succession issues. Their deal-sourcing process is both regional and national.

Manufactures Laser Induced Fluorescence (LIF) detectors

Manufactures refrigerated and insulated containers

Manufactures and distributes disinfection equipments and products

SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia.

Develops AI-enabled software and hardware platform for shared mobility

Manufactures coloring powers, extracts and concentrates for food, cosmetics and pharmaceutical industry